^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    prizloncabtagene autoleucel (JNJ-4496)

    i
    Other names: JNJ-4496, JNJ-90014496, C-CAR039, anti-CD19/20-CAR vector-transduced T cell therapy, anti-CD19/20 CART cell therapy, EXP039, CD19/CD20-directed CAR-T cells, C CAR039, EXP 039, JNJ 4496, JNJ 90014496, CCAR039, EXP-039, JNJ4496, JNJ90014496
    Company:
    AbelZeta Pharma, J&J, Tongji University
    Drug class:
    CD19-targeted CAR-T immunotherapy, CD20-targeted CAR-T immunotherapy
    Related drugs:
    4ms
    A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=385, Recruiting, Janssen Research & Development, LLC | Phase classification: P1 --> P1/2 | N=230 --> 385 | Trial primary completion date: May 2026 --> Dec 2028
    Phase classification • Enrollment change • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    prizloncabtagene autoleucel (JNJ-4496)
    6ms
    A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma (clinicaltrials.gov)
    P1, N=7, Completed, Tianjin Medical University Cancer Institute and Hospital | Active, not recruiting --> Completed
    Trial completion
    |
    CD20 positive
    |
    prizloncabtagene autoleucel (JNJ-4496)
    7ms
    A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects (clinicaltrials.gov)
    P1, N=25, Completed, Shanghai Tongji Hospital, Tongji University School of Medicine | Active, not recruiting --> Completed
    Trial completion
    |
    CD20 positive
    |
    prizloncabtagene autoleucel (JNJ-4496)
    11ms
    A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma. (PubMed, Blood)
    Patients with CD19 and/or CD20-positive r/r B-NHL received a 3-day lymphodepletion (cyclophosphamide: 300 mg/m2/d; fludarabine: 30 mg/m2/d) followed by an intravenous dose of prizlon-cel...Prizlon-cel showed a favorable safety profile and a high and durable response in patients with r/r B-NHL, suggesting a promising treatment option for patients with r/r B-NHL. (ClinicalTrials.gov number: NCT04317885, NCT04655677, NCT04696432, NCT04693676).
    P1 data • Journal
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    cyclophosphamide • fludarabine IV • prizloncabtagene autoleucel (JNJ-4496)
    11ms
    A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=230, Recruiting, Janssen Research & Development, LLC | N=104 --> 230
    Enrollment change
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    prizloncabtagene autoleucel (JNJ-4496)
    1year
    ELEVATION: A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (clinicaltrials.gov)
    P1/2, N=112, Recruiting, Shanghai AbelZeta Ltd. | Phase classification: P1b/2 --> P1/2 | N=72 --> 112 | Trial completion date: Mar 2027 --> Dec 2027 | Trial primary completion date: Mar 2027 --> Oct 2025
    Phase classification • Enrollment change • Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD20 positive • BCL6 rearrangement • BCL2 rearrangement
    |
    prizloncabtagene autoleucel (JNJ-4496)
    almost2years
    A Study of JNJ-90014496 in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=104, Recruiting, Janssen Research & Development, LLC | Trial completion date: Oct 2027 --> Oct 2028
    Trial completion date • CAR T-Cell Therapy
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    prizloncabtagene autoleucel (JNJ-4496)
    almost2years
    A Study of JNJ-90014496 in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=104, Recruiting, Janssen Research & Development, LLC | Trial completion date: Apr 2027 --> Oct 2027
    Trial completion date • CAR T-Cell Therapy
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    prizloncabtagene autoleucel (JNJ-4496)
    2years
    A Study of JNJ-90014496 in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=92, Recruiting, Janssen Research & Development, LLC | N=52 --> 92 | Trial completion date: Oct 2027 --> Apr 2027
    Enrollment change • Trial completion date • CAR T-Cell Therapy
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    prizloncabtagene autoleucel (JNJ-4496)
    2years
    A Study of JNJ-90014496 in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=52, Recruiting, Janssen Research & Development, LLC | N=15 --> 52 | Trial completion date: Jul 2038 --> Oct 2027 | Trial primary completion date: May 2025 --> May 2026
    Enrollment change • Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    prizloncabtagene autoleucel (JNJ-4496)
    over2years
    A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma (clinicaltrials.gov)
    P1, N=7, Active, not recruiting, Tianjin Medical University Cancer Institute and Hospital | Recruiting --> Active, not recruiting | N=10 --> 7 | Trial completion date: Oct 2022 --> Dec 2023 | Trial primary completion date: Jul 2022 --> Jul 2023
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    CD20 positive
    |
    prizloncabtagene autoleucel (JNJ-4496)
    over2years
    A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects (clinicaltrials.gov)
    P1, N=25, Active, not recruiting, Shanghai Tongji Hospital, Tongji University School of Medicine | Recruiting --> Active, not recruiting | Trial completion date: Aug 2021 --> Dec 2023 | Trial primary completion date: Aug 2021 --> Jun 2023
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    CD20 positive
    |
    prizloncabtagene autoleucel (JNJ-4496)